{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:55:18Z","timestamp":1790621718923,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":1260,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T00:00:00Z","timestamp":1561161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jsm.jsexmed.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Traditionally, surgery has been considered the gold standard treatment for Peyronie\u2019s disease (PD). Less-invasive alternatives, such as collagenase Clostridium histolyticum (CCH) and traction therapy, have been proposed and proven effective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To compare cost-effectiveness of management options for PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Markov analytic model was created to compare the cost-effectiveness of treatment with a novel traction device, RestoreX (RXPTT), vs CCH vs surgery. Outcomes were derived from single-institution, prospective data of 63 men treated with RXPTT, 115 with CCH, and 23 with plication or incision and grafting. Costs were based on 2017 Medicare reimbursement and utility values from the literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Model outcomes included complications for each treatment arm, as well as the probability of success, which was defined as \u226520% improvement in curvature. Univariable and multivariable sensitivity analyses were performed to test the robustness of the model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall success rates were 96% (surgery), 66% (CCH), and 48% (RXPTT). At 10 years after treatment, RXPTT was the most cost-effective, with mean costs per patient of $883 (RXPTT), $11,419 (surgery), and $33,628 (CCH). CCH and surgery both resulted in a gain of quality adjusted life years (QALYs) relative to RXPTT (9.44 and 9.36 vs 9.27, respectively). Sensitivity analysis demonstrated greater cost-effectiveness for surgery if lower (\u226446%) rates of postoperative erectile dysfunction or length loss (\u22643%). CCH became more cost-effective at lower costs (\u2264$16,726) or higher success rates (\u226576%). On multivariable sensitivity analysis at a willingness to pay threshold of $100,000\/QALY, the most cost-effective strategy was RXPTT in 49%, surgery in 48%, and CCH in 3% of simulations. At a willingness to treat threshold of $150,000\/QALY, the most cost-effective treatment option was RXPTT in 33%, surgery in 55%, and CCH in 12% of simulations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>In an era of value-based care, this model can guide cost-effective treatment selection on the basis of provider, patient, and payer characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths &amp; Limitations<\/jats:title>\n                  <jats:p>The current study represents the first cost-effectiveness comparison of treatment modalities for PD and is strengthened by prospective data collection, large CCH and traction sample sizes, and robust sensitivity analyses. Consistent with cost-effective models, the model is limited by assumptions and may not apply to all scenarios.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>RXPTT represents a more cost-effective method for achieving \u226520% curvature improvement compared with surgery or CCH. Depending on treatment goals, rate of surgical complications, and willingness to pay threshold, surgery and CCH may become more cost-effective in select scenarios.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1016\/j.jsxm.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T21:29:23Z","timestamp":1564003763000},"page":"1421-1432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Comparative Cost-effectiveness of Surgery, Collagenase <i>Clostridium Histolyticum<\/i>, and Penile Traction Therapy in Men with Peyronie\u2019s Disease in an Era of Effective Clinical Treatment"],"prefix":"10.1093","volume":"16","author":[{"given":"Kevin","family":"Wymer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Trost","sequence":"additional","affiliation":[{"name":"Department of Urology , Rochester, MN , USA"},{"name":"Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"2023010721202082700_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.urpr.2016.04.005","article-title":"Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie\u2019s disease deformities","volume":"4","author":"Cordon","year":"2017","journal-title":"Urol Pract"},{"key":"2023010721202082700_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.21037\/tau.2016.03.16","article-title":"Grafting techniques for Peyronie\u2019s disease","volume":"5","author":"Hatzichristodoulou","year":"2016","journal-title":"Transl Androl Urol"},{"key":"2023010721202082700_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.juro.2012.08.194","article-title":"Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis","volume":"189","author":"Adibi","year":"2013","journal-title":"J Urol"},{"key":"2023010721202082700_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.urology.2014.10.026","article-title":"Corporoplasty using buccal mucosa graft in Peyronie disease: Is it a first choice?","volume":"85","author":"Zucchi","year":"2015","journal-title":"Urology"},{"key":"2023010721202082700_bib5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1743-6109.2010.02102.x","article-title":"Five-year follow-up of Peyronie\u2019s graft surgery: Outcomes and patient satisfaction","volume":"8","author":"Chung","year":"2011","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"2023010721202082700_bib7","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"key":"2023010721202082700_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0022-5347(17)53599-5","article-title":"Mechanisms of calcification in Peyronie\u2019s disease","volume":"127","author":"Vande Berg","year":"1982","journal-title":"J Urol"},{"key":"2023010721202082700_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: Results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"BJU Int"},{"key":"2023010721202082700_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: An important predictor of collagenase Clostridium Histolyticum treatment outcomes for men with Peyronie\u2019s disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"2023010721202082700_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jsm.12400","article-title":"Acute phase Peyronie\u2019s disease management with traction device: A nonrandomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Mart\u00ednez-Salamanca","year":"2014","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1743-6109.2008.01108.x","article-title":"Use of penile extender device in the treatment of penile curvature as a result of Peyronie\u2019s disease. Results of a phase II prospective study","volume":"6","author":"Gontero","year":"2009","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib13","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","article-title":"Penile traction therapy for treatment of Peyronie\u2019s disease: A single-center pilot study","volume":"5","author":"Levine","year":"2008","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib14","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device \u201cPenimaster PRO\u201d is effective and safe in the stable phase of Peyronie\u2019s disease: A controlled multicentre study","volume":"123","author":"Moncada","year":"2019","journal-title":"BJU Int"},{"key":"2023010721202082700_bib15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","article-title":"The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie\u2019s disease","volume":"194","author":"Yafi","year":"2015","journal-title":"J Urol"},{"key":"2023010721202082700_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease","volume":"9","author":"Abern","year":"2012","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"2023010721202082700_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000000245","article-title":"Outcomes of a novel penile traction device (Restorex) in men with Peyronie\u2019s disease: A randomized, single-blinded, controlled trial","author":"Ziegelmann","year":"2019","journal-title":"J Urol"},{"key":"2023010721202082700_bib19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with intralesional collagenase Clostridium histolyticum injection for Peyronie\u2019s disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol"},{"key":"2023010721202082700_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1743-6109.2005.20113.x","article-title":"A surgical algorithm for men with combined Peyronie\u2019s disease and erectile dysfunction: Functional and satisfaction outcomes","volume":"2","author":"Mulhall","year":"2005","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU guidelines on penile curvature","volume":"62","author":"Hatzimouratidis","year":"2012","journal-title":"Eur Urol"},{"key":"2023010721202082700_bib22","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie\u2019s disease: Evidence-based 2010 Guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib23","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1743-6109.2011.02299.x","article-title":"Erectile Dysfunction after Plaque Incision and Grafting: Short-term assessment of incidence and predictors","volume":"8","author":"Flores","year":"2011","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2023010721202082700_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"2023010721202082700_bib26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014The curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"2023010721202082700_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"key":"2023010721202082700_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"PharmacoEconomics"},{"key":"2023010721202082700_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.urology.2015.04.047","article-title":"Self-report and clinical response to Peyronie\u2019s disease treatment: Peyronie\u2019s disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies","volume":"86","author":"Hellstrom","year":"2015","journal-title":"Urology"},{"key":"2023010721202082700_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.urology.2017.11.012","article-title":"Conservatively managed Peyronie\u2019s disease-long-term survey results from patients undergoing nonsurgical and noninjection therapies","volume":"113","author":"Ziegelmann","year":"2018","journal-title":"Urology"},{"key":"2023010721202082700_bib31","doi-asserted-by":"crossref","first-page":"e760","DOI":"10.1016\/j.juro.2017.02.1769","article-title":"MP56-16 patient\u2019s choice of health information and treatment modality for Peyronie\u2019s disease","volume":"197","author":"Bole","year":"2017","journal-title":"J Urol"},{"key":"2023010721202082700_bib32","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jsxm.2019.01.121","article-title":"111 Long-term safety and curvature deformity characterization in patients previously treated with collagenase Clostridium histolyticum for Peyronie\u2019s disease","volume":"16","author":"Goldstein","year":"2019","journal-title":"J Sex Med"},{"key":"2023010721202082700_bib33","article-title":"Mp65-18 preliminary outcomes of a novel penile traction device (restorex) in men with Peyronie\u2019s disease: A randomized, controlled trial","volume":"201","author":"Ziegelmann","year":"2019","journal-title":"J Urol"},{"key":"2023010721202082700_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older","volume":"43","author":"Stewart","year":"2005","journal-title":"Med Care"},{"key":"2023010721202082700_bib35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.320.7243.1165","article-title":"Cost utility analysis of sildenafil compared with papaverine-phentolamine injections","volume":"320","author":"Stolk","year":"2000","journal-title":"BMJ"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951931269X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174360951931269X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/9\/1421\/48476974\/jsm_16_9_1421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/16\/9\/1421\/48476974\/jsm_16_9_1421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T21:21:24Z","timestamp":1673126484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/16\/9\/1421\/6966804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,24]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.06.010","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie\u2019s Disease in an Era of Effective Clinical Treatment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Sexual Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsxm.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.","name":"copyright","label":"Copyright"}]}}